Philips and Yale expand research deal

Royal Philips (NYSE:PHG) said today it expanded its master research agreement with Yale School of Medicine to include a new research program looking to develop innovations in interventional oncology. The multi-year cancer research program aims to explore new concepts in image-guided therapies, diagnostic imaging and informatics, Philips said, and will engage with multiple research groups at Yale. “Over the past few years there have been significant developments in image-guided therapy to locally treat tumors, with the result that interventional oncology procedure volumes have grown rapidly. However, the biggest remaining challenge is that it is difficult to predict the effectiveness of the procedure. Together with Philips, we are embarking on a new multi-year research program with the aim to redefine and standardize this type of minimally-invasive treatment to achieve more predictable and better controlled procedure outcomes, and ultimately enhanced patient care,” research program lead Jeff Geschwind said in a press release. A team of clinical scientists from Philips will operate with Geschwild’s team at Yale in a recently established facility seeking to shift research results into innovations for patient care, the company said. “We are on a mission to enhance existing interventional oncology procedures and enable new ones that offer predictable and effective minimally invasive options for treating cancerous lesions. Our new collaboration wit...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Diagnostics Oncology Research & Development Royal Philips Source Type: news

Related Links:

In this study, we compared the long-term side effects of proton radiation to equivalent doses of X-rays in the initiation and progression of premalignant lesions in a lung cancer susceptible mouse model (K-rasLA1). We show proton irradiation causes more complex DNA damage that is not completely repaired resulting in increased oxidative stress in the lungs both acutely and persistently. We further observed K-rasLA1 mice irradiated with protons had an increased number and size of initiated and premalignant lesions and adenomas that were often infiltrated with inflammatory cells. Proton irradiated mice had a lower median surv...
Source: Life Sciences in Space Research - Category: Biology Source Type: research
CONCLUSION: This approach merging qualitative and quantitative data suggests that mMCC patients report a better experience with avelumab than with chemotherapy. PMID: 30107762 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
Local Anesthetics as…Cancer Therapy? Anesth Analg. 2018 Sep;127(3):601-602 Authors: Lynch C PMID: 30113976 [PubMed - in process]
Source: Anesthesia and Analgesia - Category: Anesthesiology Authors: Tags: Anesth Analg Source Type: research
Publication date: Available online 17 August 2018Source: Biosensors and BioelectronicsAuthor(s): Haihua Wang, Mengjie Li, Yingning Zheng, Tao Hu, Yaqin Chai, Ruo YuanAbstractThough preferable progresses have been achieved to improve the photoelectric performance of fullerene (C60 NPs) by sensitized structure in photoelectrochemical (PEC) field, further application inevitably suffers from the inherent scarcities of heavy metal-involved quantum dots as sensitizers containing restricted sensitization effect, complex preparation and biological toxicity. In this work, a PEC biosensor based on [Ru(dcbpy)2dppz]2+/Rose Bengal dyes...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Photochem. Photobiol. Sci., 2018, Advance Article DOI: 10.1039/C8PP00271A, PerspectivePaula Garc ía Calavia, Gordon Bruce, Lluïsa Pérez-García, David A. Russell A review describing the state-of-the-art of the functionalisation of gold nanoparticles with photosensitisers and targeting ligands for photodynamic cancer therapy. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Photochem. Photobiol. Sci. latest articles - Category: Chemistry Authors: Source Type: research
Veterans who seek care for low-risk prostate cancer receive more imaging that...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Multiparametric MRI aids in prostate cancer follow-up SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment MRI-based risk model improves prostate cancer detection
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Conclusions: Use of cam, particularly biologic products, increased significantly after a cancer diagnosis. Further studies are required to examine the effect of cam use on the efficacy and safety of cancer therapies. PMID: 30111972 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
We present the first documented case of pembrolizumab-induced grade IV neutropenia. A 73-year-old women known for myositis, Crohn’s disease, and hypothyroidism and diagnosed with PD-L1 positive stage IV pulmonary adenocarcinoma is treated with Pembrolizumab. She develops grade IV neutropenia 2 weeks after her second infusion. She is therefore hospitalized and treated initially with corticosteroids, granulocyte colony-stimulating factor, and intravenous immunoglobulins. Given the persistent neutropenia, cyclosporine was added, but quickly stopped owing to fever. The patient recovered her neutrophils 6.5 weeks after he...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Contributors : Matthias Dobbelstein ; Anusha SriramanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCDK4 inhibitors have reached clinical approval for cancer therapy. In parallel, the p53 antagonist Mdm2 remains an attractive target for anti-cancer therapy, including numerous clinical studies. The genes encoding Mdm2 and CDK4 are frequently co-amplified in human malignancies, most notably in liposarcomas, suggesting their combined targeting for therapy. Here we show, however, that small compounds that inhibit Mdm2 and CDK4 antagonize each other rather than synergize in their cytotoxi...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
AbstractGenomic medicine provides opportunities to personalize cancer therapy for an individual patient. Although novel targeted therapies prolong survival, most patients with cancer continue to suffer from burdensome symptoms including pain, depression, neuropathy, nausea and vomiting, and infections, which significantly impair quality of life. Suboptimal management of these symptoms can negatively affect response to cancer treatment and overall prognosis. The effect of genetic variation on drug response—otherwise known as pharmacogenomics—is well documented and directly influences an individual patient's resp...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Symptom Management and Supportive Care, Precision Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Liver | Medical Devices | Urology & Nephrology | Yale